



Functional genomics identifies type I interferon pathway as central for host defense against *Candida albicans*

Citation

Smeeckens, S. P., A. Ng, V. Kumar, M. D. Johnson, T. S. Plantinga, C. van Diemen, P. Arts, et al. 2013. "Functional genomics identifies type I interferon pathway as central for host defense against *Candida albicans*." *Nature communications* 4 (1): 1342. doi:10.1038/ncomms2343. <http://dx.doi.org/10.1038/ncomms2343>.

Published Version

doi:10.1038/ncomms2343

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717637>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Published in final edited form as:

Nat Commun. 2013 ; 4: 1342. doi:10.1038/ncomms2343.

Functional genomics identifies type I interferon pathway as central for host defense against *Candida albicans*

Sanne P. Smeekeens^{1,2,*}, Aylwin Ng^{3,4,*}, Vinod Kumar^{5,*}, Melissa D. Johnson^{6,7}, Theo S. Plantinga^{1,2}, Cleo van Diemen⁵, Peer Arts⁸, Eugène T.P. Verwiel⁸, Mark S. Gresnigt^{1,2}, Karin Fransen⁵, Suzanne van Sommeren⁵, Marije Oosting^{1,2}, Shih-Chin Cheng^{1,2}, Leo A.B. Joosten^{1,2}, Alexander Hoischen⁸, Bart-Jan Kullberg^{1,2}, William K. Scott⁹, John R. Perfect^{6,7}, Jos W.M. van der Meer^{1,2}, Cisca Wijmenga⁵, Mihai G. Netea^{1,2,#}, and Ramnik J. Xavier^{3,4}

¹Department of Medicine (463), Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands ²Nijmegen Institute for Infection, Inflammation, and Immunity (N4i) (463), PO Box 9101, 6500 HB Nijmegen, The Netherlands ³The Broad Institute of Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge MA 02142, USA ⁴Center for Computational and Integrative Biology and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston MA 02114, USA ⁵Department of Genetics, University Medical Centre Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands ⁶Duke University Medical Center, Duke Box 102359, Durham NC 27710 NC, USA ⁷Department of Clinical Research, Campbell University School of Pharmacy, PO Box 1090, Buies Creek NC 27506, USA ⁸Department of Human Genetics (855), Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands ⁹Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, 1501 NW 10th Avenue Miami FL 33136, USA

Abstract

Candida albicans is the most common human fungal pathogen causing mucosal and systemic infections. However, human antifungal immunity remains poorly defined. Here, by integrating transcriptional analysis and functional genomics, we identified *Candida*-specific host defense mechanisms in humans. *Candida* induced significant expression of genes from the type I interferon (IFN) pathway in human peripheral blood mononuclear cells. This unexpectedly prominent role of type I IFN pathway in anti-*Candida* host defense was supported by additional evidence. Polymorphisms in type I IFN genes modulated *Candida*-induced cytokine production and were correlated with susceptibility to systemic candidiasis. In *in-vitro* experiments, type I IFNs skewed *Candida*-induced inflammation from a Th17-response toward a Th1-response. Patients with chronic mucocutaneous candidiasis displayed defective expression of genes in the type I IFN pathway. These findings indicate that the type I IFN pathway is a main signature of *Candida*-induced inflammation and plays a crucial role in anti-*Candida* host defense in humans.

#Address for correspondence: Department of Medicine (463) Radboud University Nijmegen Medical Center Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands Tel: +31-24-3618819, Fax: +31-24-3541734 m.netea@aig.umcn.nl.

*These authors contributed equally to this work.

The authors declare no conflicting financial interests.

Transcriptomics data have been deposited in the Gene Expression Omnibus (GEO) database under accession code GSE42606.

AUTHOR CONTRIBUTIONS L.A.B.J., W.K.S., J.R.P., J.W.M.M., C.W., M.G.N. and R.J.X. designed the research, S.P.S., A.N., V.K., M.D.J., T.S.P., P.A., E.T.V., A.H., C.D., A.G., M.S.G., K.F., S.S., M.O., S.C.C. performed the research and analyzed the data, S.P.S., A.N., V.K., C.W., M.G.N. and R.J.X. interpreted the data and wrote the paper.

Introduction

Candida albicans (*C. albicans*) is a commensal microorganism that inhabits human skin and mucosa. *Candida* can be isolated from up to 70% of the general population at any given moment, and it is believed that all individuals have been colonized with *Candida* at a some point¹. Although it is a commensal organism, *C. albicans* can also cause mucosal and systemic infections, especially in immunocompromised hosts². Despite the availability of novel classes of antifungal agents (e.g., azoles, echinocandins), mortality due to systemic candidiasis, the fourth most common form of sepsis³⁻⁵, reaches 37-44%^{3, 6, 7}. In addition, vaginal and oral candidiasis can also occur in healthy or only mildly immunocompromised individuals⁸, with up to 5% of women in the general population suffering from recurrent vulvovaginal candidiasis⁹.

Despite the introduction of modern antifungal drugs and intensive care facilities, progress in improving the outcome of *Candida* infections in the last decade has been disappointing. Given this lack of progress, it is currently believed that only adjuvant immunotherapy will be able to further reduce the burden of morbidity and mortality caused by *C. albicans* infections¹⁰. Understanding the host defense pathways involved in candidiasis is therefore crucial for identifying novel targets for immunotherapy. To date, all investigations aimed at identifying antifungal host defense mechanisms in humans have relied on candidate-target approaches that are based on biologic plausibility of hypotheses extracted from *in vitro* or animal studies. While this approach has been fruitful in confirming important pathways of antifungal defense, it has lacked the power to provide a hierarchy of the importance of these pathways, and to identify potentially novel and unexpected host defense mechanisms against *Candida*.

In the present study, we have taken an alternative, unbiased approach to this biological problem. Using a combination of transcriptional analysis and systems biology, we have stimulated human primary cells with the fungus, identifying *Candida*-specific transcription profiles in human immune cells. While *C. albicans* induced the transcription of multiple inflammatory gene sets commonly stimulated by other inflammatory stimuli, it also specifically induced several additional gene sets, among which we identified an unexpectedly strong type I IFN signature profile. We confirmed the importance of the type I IFN pathway for anti-*Candida* host defense in humans through immunological and genetic studies in both healthy volunteers and in patients with systemic candidiasis or suffering from chronic mucocutaneous candidiasis (CMC).

RESULTS

Candida albicans induces a type I interferon response

We measured genome-wide transcriptional profiles in peripheral blood mononuclear cells (PBMCs) from healthy volunteers upon stimulation with *C. albicans*, as well as with inflammatory stimuli unrelated to fungal pathogens: *Escherichia coli*-derived lipopolysaccharide (LPS), *Borrelia burgdorferi*, *Mycobacterium tuberculosis* (MTB), and RPMI culture medium as a control. Measurements were performed at 4 and 24 hours. 693 transcripts that showed >2-fold higher expression compared to corresponding RPMI stimulation were selected (BH-adjusted $P < 0.05$). K-means analysis identified profile clusters that indicated shared and specific genes that were differentially expressed in response to each stimulus. We grouped shared genes into signatures representing common early response genes (clusters 1, 6, 14, 27), common late response genes (clusters 2, 3), and common inflammatory genes induced by all stimulations (clusters 9, 21, 25) (Fig. 1a and Supplementary Fig. S1-3).

More importantly, to identify a set of discriminatory features (from the 693 differentially expressed transcripts) that would be most informative of the state of *Candida* stimulation and could distinguish *Candida* stimulation from the other inflammatory stimuli, we utilized information gain (Kullback-Leibler divergence/relative entropy) feature selection, to reduce the dimensionality of the feature space^{11, 12}. We performed 10-fold cross-validation which stratifies the data into 10 random partitions in which each (in turn) is held out for testing and the remainder for training a Bayesian classifier. Class prediction was evaluated by computing the area under the receiver-operating characteristic (ROC) curve (AUROC), which assesses true- and false-positive rates. A 101-transcript (95-gene) *Candida*-response signature (Fig. 1b and Supplementary Table S1) was defined using this supervised learning approach for class prediction, achieving an AUROC of 97.8%, which would indicate an excellent classifier performance with very high discriminative value. Principal component analysis (PCA) of the *Candida*-response signature further demonstrated good class separation on the basis of *Candida* status and stimulation duration (Fig. 1c). As a set, the 101 features collectively identify expression signatures that are informative of *Candida* stimulation across the 4-hour, 24-hour or both time-points that sufficiently distinguish *Candida* from the rest. Enrichment analysis for the 101-transcript *Candida*-response signature revealed a striking over-representation of the interferon (IFN) signaling pathway ($p=3.8 \times 10^{-35}$) (Fig. 1d and Supplementary Table S2). This set of genes was strongly induced at both 4 hours and 24 hours of *Candida* stimulation and establishes a definitive *Candida*-responsive signature distinct from that observed with LPS, MTB or *Borrelia* stimulation.

Type I IFN SNPs modulate susceptibility to candidemia

In order to assess whether the type I IFN genes specifically induced by *C. albicans* in human leukocytes are indeed involved in antifungal host defense, we investigated whether common polymorphisms in a subset of these genes influence susceptibility to systemic *Candida* infections. From a cohort of 217 Caucasian patients with candidemia, well described elsewhere^{10, 13}, we had Immunochip genotyping data available and 11 genes of the 101-transcript (95-gene) dataset were covered by the Immunochip array (Supplementary Table S3). We tested these 11 genes for association by taking immunochip data on 12,228 non-candidemia Caucasian healthy volunteers as controls¹⁴. Analysis of the loci associated with these 11 genes revealed significant association of genetic variation with susceptibility to systemic candidiasis in four regions: *CCL8* SNP 1kg_17_29697448 ($p = 0.00069$), *STAT1* SNP rs16833172 ($p = 0.0042$), *SP110* SNP rs3769845 ($p = 0.012$) and *PSMB8* SNP rs3198005 ($p = 0.01$) (Fig. 2a-d) (Supplementary Fig. S1-3, clusters 10, 11, 20, 11 respectively) (Supplementary Table S3). After applying a stringent Bonferroni correction for multiple testing, the association between susceptibility to candidemia and *STAT1* and *CCL8* remained significant. This finding confirms that the *C. albicans*-specific genes we identified in our transcriptional arrays play an important role in host defense against systemic fungal infections. We also attempted to assess whether the polymorphisms in these genes also modified disease severity. However, only 51 patients fulfilled the criteria of severe candidiasis based on clinical scores and persistence of positive blood cultures, and this number was too low for allowing the identification of significant differences between genetic variation and disease severity (disseminated disease, persistent fungemia and mortality at 14 or 30 days) (data not shown).

Type I IFN SNPs modulate *Candida*-induced cytokine responses

In an additional approach to validate the role of the type I IFN pathway for host defense against *Candida*, we isolated PBMCs from an additional group of 74 healthy volunteers and stimulated the cells with the fungus. Genetic variation in 11 type I IFN pathway genes present on the Immunochip was correlated with *C. albicans*-induced release of TNF- α ,

IL-1 β , IL-8, IL-6, IL-10, IFN- γ and IL-17. In contrast to other microbial stimuli such as LPS and MTB, *C. albicans* induced higher levels of TNF- α , IL-1 β and IL-10 production, and lower levels of IL-8 and IL-6 in human PBMCs (Supplementary Fig. S4). The correlation of cytokine concentrations with genotypes at tag SNPs of *Candida*-induced IFN pathway genes revealed significant associations at *IRF1* and *STAT1* regions (Fig. 3a-d) in which *IRF1* SNPs were associated with TNF- α ($p = 0.0028$) and IL-10 levels ($p = 0.0024$), while *STAT1* SNPs were associated with TNF- α ($p = 0.001$) and IL-6 levels ($p = 0.0002$). Consistent with the specificity of the type I IFN pathway for *Candida* stimulation, the association was significant with cytokine levels induced by *Candida*, but not by LPS or MTB stimulation (Supplementary Fig. S5).

Type I IFNs skew cytokine responses from Th17 towards Th1

To investigate the importance of type I IFN signaling in host defense against *Candida*, PBMCs from healthy individuals were stimulated with heat-killed *C. albicans*. In line with the transcriptional profile described above (Fig. 1), IFN- β could be detected in cell culture supernatants only after *C. albicans* stimulation. In contrast, neither live (Fig. 4a), nor heat-killed *C. albicans* induced any detectable IFN- α production.

We next assessed the role of type I IFN pathways in the induction of cytokines by *C. albicans*. When PBMCs were stimulated with heat-killed *C. albicans* in the presence of an antibody against IFN- $\alpha/\beta/\omega$ receptor 1 (IFNAR), IFN- γ production was significantly lower compared to PBMCs stimulated in the presence of a control antibody. Blocking of IFNAR did not influence the production of the monocyte-derived cytokines IL- β or TNF- α (Fig. 4b). Conversely, adding IFN- α or IFN- β to *Candida*-stimulated cells increased IFN- γ production, while significantly decreasing IL-17 and IL-22 production (Fig. 4c). Together these data suggest that type I interferons (in the context of infection, most likely IFN- β) modulate the immune reaction induced by *C. albicans*, skewing host defense toward a Th1 response.

STAT1 mutations cause reduced expression of type I IFN genes

Patients with autosomal dominant CMC have increased susceptibility to mucosal fungal infections and often carry gain-of-function mutations in *STAT1*^{15, 16}, which lead to STAT1 hyperphosphorylation, that in turn likely makes STAT1 unavailable for forming heterodimers with other STAT molecules¹⁷. In co-cultures of DCs and T-cells from CMC patients, this led to defective Th1 and Th17 responses (Supplementary Fig. S6). In order to validate the role of *Candida*-specific genes in human antifungal mucosal defense, we assessed the expression of these genes in cells from CMC patients. PBMCs from healthy controls and CMC patients were stimulated with RPMI, *E. coli*-derived LPS, heat-killed *C. albicans*, or heat-killed MTB. The expression of type I IFN pathway genes (including *IRF5*, *IRF7*, *ISG15*, *IFI44* and *IFI44L*) that are induced downstream of STAT1-STAT2 showed patterns of defective expression in CMC patients compared to healthy controls, supporting a role of the type I IFN pathway in this immunodeficiency (Fig. 5). The expression of *IRF3*, *IRF9* and IFN- β , three genes in the type I IFN pathway upstream of STAT1-STAT2, was not decreased in cells from CMC patients. In fact, *Candida* induced IFN- β expression appeared to be higher in cells from CMC patients, possibly indicating a compensatory feedback mechanism.

In order to investigate the type I IFN pathway in CMC patients in a more systematic way, we also performed RNA sequencing analysis in PBMCs stimulated with *C. albicans* from both control volunteers and CMC patients. The differential expression of 91 genes in response to *C. albicans* stimulation was compared between CMC patients and healthy controls (10 genes from the 101-gene signature characteristic for *Candida* were not

considered: 7 because another isoform was already used for FPKM calculations, and 3 hypothetical proteins without concordant refseq genes). In cells from healthy controls, two genes showed downregulation (*LFNG*, *RGC32*), while all other genes were upregulated upon stimulation (Supplementary Fig. S7), validating the previous findings based on expression array analysis. In order to observe differences between patients and controls, the standardized fold change was used to create the respective heatmap (Fig. 6). The patients show a much lower standardized fold change in genes downstream of STAT1, again supporting the role of type I IFN pathway in CMC. We found 27 genes, from the set of 91 genes, to be significantly differently regulated upon *Candida* stimulation in patients compared to controls based on an ANOVA analysis (p-value interaction group and treatment <0.05) (MX1, OAS3, IFIT2, RTP4, XAF1, OAS2, IFI44, IFIH1, IFIT3, ADAR, PRIC285, FAM46A, SAMD9L, EIF2AK2, PARP12, TRIM22, ZBP1, HERC6, RSAD2, IFNG, OAS1, STAT2, DHX58, IRF7, TNFSF10, ISG15, HERC5). To determine the role of these 27 genes we calculated Gene ontology (GO) enrichment scores using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Enriched gene clusters were generated using Functional Annotation Clustering. Gene ontology terms associated with response to type I interferon and viral infections showed significant enrichment ($p=1.09 \times 10^{-14}$) (Supplementary Table S4).

DISCUSSION

The last decade has witnessed a significant increase in knowledge related to the mechanisms involved in antifungal host defense. However, most of this knowledge is based on *in-vitro* and animal studies; these studies led to hypotheses to be tested in human systems, leading to a somewhat biased view of human immunity against fungi. In the present study we have used a different approach based exclusively on complementary human studies: transcriptomics analysis in human primary cells, correlation of genetic variability and antifungal immunity in healthy volunteers (functional genomics), case-control association studies in patients with disseminated *C. albicans* infections, and assessment of antifungal immunity in CMC patients.

In our initial approach, we designed a hypotheses-generating set of experiments by assessing the transcriptional profile induced in circulating primary leukocytes by *C. albicans*. Human primary PBMCs were stimulated either with *C. albicans* or with other inflammatory stimuli. Pathway analysis of the genes induced by *Candida* indicated two broad categories: (i) a first set of genes that was strongly induced and shared by both *C. albicans* and other inflammatory stimuli (LPS, MTB, or *B. burgdorferi*), constituted expected pathways involved in inflammation and innate immunity, many of which have important roles in antifungal immunity¹⁸, and (ii) a feature set comprising an expression signature of 101 transcripts (95 genes) that distinguishes the *Candida*-specific response and is characterized by a strikingly strong and unanticipated type I IFN response.

Because the identification of the type I IFN pathway as the most prominent *Candida*-specific transcriptional signature was surprising, we initiated a series of studies to confirm this finding. Firstly, we assessed whether genetic polymorphisms in several of the genes identified in the *Candida*-specific dataset influenced susceptibility to systemic *Candida* infections. In a cohort of patients with candidemia that were genotyped using the Immunochip platform (Illumina¹⁴), on which 11 genes of the *Candida*-specific dataset were covered, we identified significant association of genetic variation with susceptibility to candidiasis in four of these genes: *CCL8* locus, *STAT1*, *SP110* locus, and *PSMB8* locus. This finding confirms that genes from the 101 *Candida*-specific dataset influence susceptibility to systemic fungal infections.

Secondly, the role of the type I IFN pathway for the anti-*Candida* immune response was subsequently validated in a study in which PBMCs isolated from a group of healthy volunteers were stimulated with the fungus. Genetic variation in the 11 type I IFN pathway genes present on the Immunochip was correlated with *C. albicans*-induced cytokine **production**. The correlation of cytokine concentrations with genotypes at tag SNPs of *Candida*-induced IFN pathway genes revealed significant associations at *IRF1* and *STAT1* regions, both crucial components of type I IFN pathway. We cannot exclude however that the effect of these polymorphisms on TNF α production are exerted through type II interferons; IFN γ is stimulated by type I interferons¹⁹, and is known to induce TNF- α production²⁰. These data support the hypothesis of the specificity of the type I IFN pathway for *Candida* stimulation, as this association was significant only for cytokine production induced by *Candida*, but not by other stimuli.

Thirdly, we performed classical immunological studies to assess the role of type I IFNs for *Candida*-induced immune responses, and we demonstrated that type I IFNs induced by *Candida* modulate Th1/Th17 cytokine profiles; IFN α and IFN β increased IFN γ production, while decreasing IL-17 production. Moschen et al previously demonstrated that type I interferons decrease IL-17 production *in vitro* and *in vivo*.²¹ TNF- α production did not seem to be influenced by blocking the IFNAR, suggesting that genetic effects in STAT1 exert their effect on TNF- α production either through direct intracellular pathways, or indirectly through IFN γ . Interestingly *C. albicans* seems to induce only IFN- β , rather than IFN- α , consistent with earlier studies in mice^{22, 23}.

Finally, using both qPCR and RNA sequencing analysis, we demonstrated that the expression of type I IFN pathway-induced genes was defective in CMC patients harboring a gain of function mutation in STAT1¹⁵. These mutations lead to increased STAT1 phosphorylation and IFN γ signaling. Liu et al demonstrated increased STAT1 phosphorylation in response to IFN γ stimulation in U3C cells transfected with mutated STAT1¹⁶. They hypothesize that IFN targeted genes can lead to decreased IL-17 production. However, freshly isolated PBMC from CMC patients do not produce any IFN γ in response to *C. albicans* stimulation¹⁵. Therefore, it is more likely that the inability of mutated STAT1 to form heterodimers with STAT3 and STAT4 causes defective Th1/Th17 responses¹⁷, which are likely to represent the main immunological defect in this disease. Additional defects in the expression of type I interferon-induced genes, as shown here, may also contribute to the increased susceptibility to mucosal fungal infections. Whether this is truly caused by a defect in STAT1-STAT2 heterodimerization remains to be demonstrated.

Taken together, these complementary studies represent a compelling body of evidence that the type I IFN pathway is an important component of the immune response during infections with *C. albicans* in humans. Moreover, the data presented here are supported by emerging information from murine studies. For example, Bourgeois *et al.* and Biondo *et al.* have reported that mouse conventional dendritic cells produce IFN- β upon stimulation with *Candida* spp. and have proposed a role for MyD88, TLR7 and TLR9 in this induction^{22, 23}. On the other hand, these results are relatively surprising, as no earlier study has reported a role for type I IFNs in human antifungal host defense. In this respect, primary immunodeficiencies in type I IFN pathway are mainly associated with viral, rather than fungal, infections²⁴. Therefore, our data suggest that type I IFN defects determine an increase susceptibility risk for fungal infections, as demonstrated here by the association with candidemia in risk groups, rather than an overt immunodeficiency associated with severe fungal infections.

The precise effect of type I IFNs for anti-*Candida* host defense is still being debated. One study in type I IFNAR knockout mice suggested a deleterious role for this pathway²²,

whereas another study reported that *IFNAR*^{-/-} mice die from their inability to control fungal growth²³. While type I IFNs play an important role in the immune response against viral infections²⁵, they seem to be deleterious in bacterial infections²⁶. In humans with *Candida* infections, the role of type I IFNs is not yet settled, although the defects seen in type I IFN gene expression in CMC patients, the susceptibility to candidemia by *STAT1* polymorphisms, and the potentiation of Th1 responses by type I IFNs, all suggest a beneficial effect of the type I IFN pathway in human antifungal host defense.

Although viruses have long been known to induce type I IFN production, other microorganisms have been recently reported to induce this pathway. MTB stimulation induces the expression of *IFNB* and *IFNA1* in human macrophages²⁷ and in murine bone marrow-derived macrophages²⁸; type I IFNs are required for caspase-1 activation during *Francisella tularensis* infection²⁹; and *Listeria monocytogenes* induces the transcription of *IFNB* in macrophages³⁰. However, the complete transcriptional profile of the type I IFN pathway performed here shows important differences from the type I IFN profile induced by MTB³¹ and is significantly more pronounced for *Candida* than for MTB (Supplementary Fig. S4). Interestingly, the very strong induction of type I IFN pathway genes by *Candida* may explain the well-known, yet unexplained, beneficial effects of injecting *Candida*-derived extracts for the treatment of warts in patients^{32, 33}.

In summary, this work presents complementary arguments from several studies to propose that the type I IFN pathway plays an important role in the immune responses to the fungal pathogen *C. albicans* in humans. The cross-validation between these approaches supports the value of this systems biology approach, combining transcriptomics with functional genomics and immunological data. Using this approach, we have confirmed the role of pathways known to be involved in antifungal host defense (e.g., common inflammatory pathways and the Th1/Th17 pathways) and we have identified a novel pathway (the type I IFN pathway). It is expected that this knowledge will have an important contribution in devising novel immunotherapeutic strategies for fungal infections, as well as influencing decision-making for vaccine design.

METHODS

Study populations

For assessing the transcriptome and the cytokine production capacity, blood was collected after written informed consent from healthy volunteers. Adult patients with candidemia were enrolled after informed consent (or waiver as approved by the Institutional Review Board) at the Duke University Hospital (DUMC, Durham, North Carolina, USA) and Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen, The Netherlands). The study was approved by the Institutional Review Boards at each study center, and enrollment occurred between January 2003 and January 2009³⁴. The study was performed in accordance with the declaration of Helsinki. In addition, blood was collected from two patients with CMC (on two different occasions) and eight healthy controls in order to investigate the induction of IFN genes by *Candida*. After informed consent was given, blood was collected by venipuncture into 10 ml EDTA syringes (Monoject, s-Hertogenbosch, The Netherlands).

PBMC isolation

Separation and stimulation of peripheral blood mononuclear cells (PBMCs) was performed as described previously³⁵. Briefly, the PBMC fraction was obtained by density centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed twice in saline and suspended

in culture medium. The cells were counted in a hemocytometer and their number was adjusted to $5 \cdot 10^6/\text{mL}$.

Cell stimulation

For the transcriptome analysis, cells were stimulated for 4 or 24 hours with RPMI, heat-killed *Borrelia burgdorferi*³⁶, *Candida albicans* (UC 820)($1 \cdot 10^6/\text{mL}$)³⁷, *Mycobacterium tuberculosis* ($1 \mu\text{g}/\text{mL}$) or *E. coli*-derived LPS ($10 \text{ ng}/\text{mL}$). In order to correlate cytokine production to SNPs in the type I IFN pathway, 5×10^5 PBMCs from healthy volunteers were stimulated with heat-killed *C. albicans* ($1 \cdot 10^6/\text{mL}$) for 24 hours. In order to investigate the effect of type I IFNs on cytokine production, 5×10^5 PBMCs were stimulated with heat-killed *C. albicans* ($1 \cdot 10^6/\text{mL}$) in the absence or presence of IFN- $\alpha 2b$ ($1 \cdot 10^5 \text{ U}/\text{mL}$)(IntronA, SP Labo N.V., Heist-op-den-berg, Belgium), IFN- β ($10 \text{ ng}/\text{mL}$), or anti-IFNAR ($100 \text{ ng}/\text{mL}$)(21385-1, PBL Interferon Source, Piscataway, USA). To assess the development of Th1 and Th17 cells, a total of 1×10^6 mononuclear cells was added to 96-wells flat-bottom plates (Greiner). Subsequently, the monocytes within the PBMC pool were differentiated towards dendritic cells (DCs) by addition of IL-4 ($50 \text{ ng}/\text{ml}$, R&D Systems), GM-CSF ($50 \text{ ng}/\text{ml}$, R&D Systems) and 10% human serum for seven days. After every second day, half of the medium was replaced by fresh DC differentiation medium. At day seven of the culture, cells were stimulated with 1×10^6 *Candida* conidia for another six days.

Transcriptome analysis

Global gene expression was profiled using Illumina Human HT-12 Expression BeadChip according to manufacturer's instructions. Image analysis, bead-level processing and quantile normalization of array data were performed using the Illumina LIMS platform, BeadStudio. A gene-wise linear model was fitted to the data and was performed in R programming language (<http://www.r-project.org/>), utilizing functions from Linear Models for Microarray Data³⁸. For each probe, a moderated t-statistic (with standard errors moderated across genes) was computed using a Bayesian model. The associated p values were adjusted to control the false discovery rate in multiple testing, using the Benjamini and Hochberg's (BH) method³⁹. For each transcript, Signal-to-Noise ratios (SNR) were computed for each infection or stimuli group relative to the untreated (RPMI) control group. The expression SNR profiles of transcripts identified as differentially expressed (BH-adjusted $p < 0.05$ and fold-change $> 2x$) were clustered using the K-means algorithm⁴⁰. We performed feature (attribute) selection^{41, 42} on differentially expressed transcripts using Information Gain (Kullback-Leibler divergence or relative entropy) to identify discriminatory features or transcripts that are most informative of the state of infection or stimulation. The accuracy of class prediction using a Java implementation of a naïve Bayes classifier^{42, 43} incorporating these features was evaluated using 10-fold cross-validation.

Cytokine measurements

The concentration of IL-1 β , IL-17, IL-22, TNF- α (R&D Systems, Abingdon, UK), IL-6, IL-8, IL-10, IFN- γ (Sanquin, Amsterdam, the Netherlands), and IFN- α , IFN- β (PBL Interferon Source, Piscataway, USA) was measured in cell culture supernatants using enzyme-linked immunosorbent assay (ELISA) according to the instructions of the manufacturer.

SNP selection

DNA was isolated using the Gentra Pure Gene Blood kit (Quiagen, Venlo, The Netherlands), according to the protocol of the manufacturer. Illumina Immunochip is a custom designed High-Density array to densely genotype 186 loci associated with 12 different autoimmune or inflammatory diseases reaching genome-wide association study

significance threshold ($P < 5 \times 10^{-8}$)¹⁴. The candidemia cohort and volunteers DNA samples were genotyped on this Immunochip Illumina platform. Only SNPs in 11 of the 101-gene dataset identified earlier were studied, as the other genes were not represented on the Immunochip. We selected tag-SNPs (Supplementary Table S3) at each region that are located within ± 250 kb of the locus by employing Haploview⁴⁴ and we excluded SNPs with $r^2 \geq 0.8$ from association analysis.

Statistical analysis

Analyses were performed using PLINKv1.07^{45, 46}. We performed Multidimensional scaling (MDS) analysis to reveal genetic background of cases and controls in Candidemia cohort (Supplementary Fig. S8). The association between tag-SNPs and Candidemia susceptibility was tested by logistic regression with the first four components from MDS analysis as covariates. The correlation between cytokine levels and genotypes was tested by Wilcoxon rank sum test using R. P-values less than 0.05 was considered significant.

Real-time PCR

Two million freshly isolated PBMCs were incubated with various stimuli as described above. After 24 hours of incubation at 37°C, total RNA was extracted in 800 μ l of TRIzol reagent (Invitrogen, Breda, The Netherlands). Isolated RNA was reverse-transcribed into complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was performed using a 7300 Real-Time PCR system (Applied Biosystems, Lennik, Belgium). Primer sequences for human IFN- β : sense: 5'-ATG-ACC-AAC-AAG-TGT-CTC-CTC-C-3' and antisense: 5'-GGA-ATC-CAA-GCA-AGT-TGT-AGC-TC-3'; IRF9: sense 5'-GAT-ACA-GCT-AAG-ACC-ATG-TTC-CG-3' and antisense: 5'-TGA-TAC-ACC-TTG-TAG-GGC-TCA-3'; IRF7: sense: 5'-GCT-GGA-CGT-GAC-CAT-CAT-GTA-3' and antisense: 5'-GGG-CCG-TAT-AGG-AAC-GTG-C-3'; ISG15: sense: 5'-CGC-AGA-TCA-CCC-AGA-AGA-TCG-3' and antisense: 5'-TTC-GTC-GCA-TTT-GTC-CAC-CA-3'; IFI44: sense: 5'-ATG-GCA-GTG-ACA-ACT-CGT-TTG-3' and antisense: 5'-GCA-GGA-TCT-TTC-GTG-CAA-CC-3'; IFI44L: sense: 5'-AGG-GAA-TCA-TTT-GGC-TCT-GTA-GA-3' and antisense: 5'-AGC-CGT-CAG-GGA-TGT-ACT-ATA-AC-3'; IRF3: sense: 5'-AGA-GGC-TCG-TGA-TGG-TCA-AG-3' and antisense: 5'-AGG-TCC-ACA-GTA-TTC-TCC-AGG-3'; IRF5: sense: 5'-GGG-CTT-CAA-TGG-GTC-AAC-G-3' and antisense: 5'-GCC-TTC-GGT-GTA-TTT-CCC-TG-3'. B2M was used as a reference gene, for which the primers were: 5'-ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5'-CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15 seconds, and 60°C for 1 minute.

RNA sequencing

RNA sequencing experiments were performed on 4 hour unstimulated and *C. albicans*-stimulated PBMC from three healthy controls and two CMC patients. Total RNA was isolated as described above. The RNA integrity (RNA integrity score = 7) was measured on the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA) using an Agilent RNA 6000 Pico Chip according to the manufacturer's instructions. Enrichment of mRNA was done using the MicroPoly(A)Purist Kit (Ambion, Life Technologies, Foster City, USA) according to manufacturer's instructions, starting with 5 μ g of total RNA and using two rounds of Oligo(dT) selection. Whole transcriptome library preparation was performed using the SOLiD Total RNA-Seq Kit (STaR Kit, Life Technologies) and the corresponding low input amount protocol (version July 2011, Life Technologies). In brief, 25ng high quality poly(A) RNA was fragmented by RNase III digestion, cleaned up using the PureLink RNA Micro Kit (Invitrogen, Life Technologies) and checked for quantity and size-distribution on a Agilent 2100 Bioanalyzer. RNA adapters were hybridized and ligated to the fragmented

RNA, followed by reverse transcription. After purification and size-selection of cDNA using Agencourt AMPure XP Reagent beads, the cDNA was amplified and used as input for the SOLiD system bead preparation using the SOLiD Easy bead system (E120 scale). Paired-end sequencing (50+25 bases) was performed on one flowcell of a 5500XL sequencer (Life Technologies). For each sample deep sequencing was performed resulting in a sequencing depth ranging from 75.6 million to 105.5 million paired-end reads. Paired-end colorspace reads were mapped against the human genome (hg19) using Tophat (version 1.4.1)⁴⁷. To increase mapping performance a GTF-file containing the exon boundaries of all known RefSeq genes (25,024 genes) was supplied to Tophat and the insert size was set to 110 bases. For all genes FPKM (Fragments per Kilobase per Million mapped reads) values were calculated using Cufflinks (version 2.0.0)⁴⁸. Further statistical analyses were done using Partek® Genomic Suite software (version 6.6, build 6.12.0109, Partek Inc., St. Louis, USA). Fold changes and p-values were calculated for each gene by performing a multifactorial Analysis of Variance (ANOVA) on log2 (with an offset of 1.0) transformed FPKM expression values. Factors included in the ANOVA model were group (patient or control), treatment (stimulation status), individual (data from same individual), and the interaction between group and treatment. Fold changes for the heatmaps were calculated for each individual by dividing the FPKM expression values of the *C. albicans* stimulated sample by the unstimulated (RPMI) sample. Fold changes with values below 1 were replaced by the negative of the inverse. A gene list containing 101 differentially expressed transcripts known from the expression array was used to select genes for further downstream analysis. Of this list, 10 transcripts were not considered; 7 because another isoform was already used for FPKM calculations, and 3 hypothetical proteins without concordant refseq genes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

RJX was supported by National Institutes of Health grants AI062773, DK043351 and DK83756 and the Helmsley Trust. MGN was supported by an ERC Consolidator grant (ERC-310372). The work in the group of CW is financially supported by the Coeliac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and funded by the Dutch Government (BSIK03009), and by the Netherlands Organization for Scientific Research (NWO VICI grant 918.66.620). We would like to thank Fadi Towfic for helpful discussions, Mathieu Platteel, Astrid Maatman, Soesma Medema-Jankipersadsing, Rutger Modderman, Judith Land and Gosia Trynka for assisting in the stimulation experiments, RNA and DNA analysis, and microarray experiments (immunochip and gene expression). Furthermore, the authors thank Kornelia Neveling and Petra de Vries for technical assistance with the RNA sequencing experiments.

REFERENCES

1. Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by *Candida* species: epidemiology, infection process and virulence attributes. *Current drug targets*. 2005; 6:863–874. [PubMed: 16375670]
2. Wingard JR, Merz WG, Saral R. *Candida tropicalis*: a major pathogen in immunocompromised patients. *Ann. Intern. Med.* 1979; 91:539–543. [PubMed: 384857]
3. Wisplinghoff H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis.* 2004; 39:309–317. [PubMed: 15306996]
4. Wisplinghoff H, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. *The Pediatric infectious disease journal*. 2003; 22:686–691. [PubMed: 12913767]

5. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis*. 2003; 36:1103–1110. [PubMed: 12715303]
6. Leroy O, et al. Epidemiology, management, and risk factors for death of invasive *Candida* infections in critical care: a multicenter, prospective, observational study in France (2005–2006). *Crit. Care Med*. 2009; 37:1612–1618. [PubMed: 19325476]
7. Moran C, Grussemeyer CA, Spalding JR, Benjamin DK Jr. Reed SD. Comparison of costs, length of stay, and mortality associated with *Candida glabrata* and *Candida albicans* bloodstream infections. *Am. J. Infect. Control*. 2010; 38:78–80. [PubMed: 19836856]
8. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. *Ann. N. Y. Acad. Sci*. 1988; 544:547–557. [PubMed: 3063184]
9. Sobel JD. Vulvovaginal candidosis. *Lancet*. 2007; 369:1961–1971. [PubMed: 17560449]
10. Johnson MD, et al. Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. *Clin Infect Dis*. 2011
11. Li T, Zhang C, Ogiwara M. A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expression. *Bioinformatics*. 2004; 20:2429–2437. [PubMed: 15087314]
12. Dudoit S, F. J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. *J. Am. Stat. Assoc*. 2002; 97:77–87.
13. Plantinga TS, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. *The Journal of infectious diseases*. 2012; 205:934–943. [PubMed: 22301633]
14. Trynka G, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nature genetics*. 2011; 43:1193–1201. [PubMed: 22057235]
15. van de Veerdonk FL, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. *The New England journal of medicine*. 2011; 365:54–61. [PubMed: 21714643]
16. Liu L, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *The Journal of experimental medicine*. 2011; 208:1635–1648. [PubMed: 21727188]
17. Smeekens SP, et al. STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis. *PloS one*. 2011; 6:e29248. [PubMed: 22195034]
18. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of *Candida albicans* by the innate immune system. *Nat Rev Microbiol*. 2008; 6:67–78. [PubMed: 18079743]
19. Way SS, Havenar-Daughton C, Kolumam GA, Orgun NN, Murali-Krishna K. IL-12 and type-I IFN synergize for IFN-gamma production by CD4 T cells, whereas neither are required for IFN-gamma production by CD8 T cells after *Listeria monocytogenes* infection. *J Immunol*. 2007; 178:4498–4505. [PubMed: 17372008]
20. Vila-del Sol V, Punzon C, Fresno M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. *J Immunol*. 2008; 181:4461–4470. [PubMed: 18802049]
21. Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivo. *Immunobiology*. 2008; 213:779–787. [PubMed: 18926293]
22. Bourgeois C, et al. Conventional dendritic cells mount a type I IFN response against *Candida* spp. requiring novel phagosomal TLR7-mediated IFN-beta signaling. *J Immunol*. 2011; 186:3104–3112. [PubMed: 21282509]
23. Biondo C, et al. Recognition of yeast nucleic acids triggers a host-protective type I interferon response. *European journal of immunology*. 2011; 41:1969–1979. [PubMed: 21480215]
24. Sancho-Shimizu V, de Diego RP, Jouanguy E, Zhang SY, Casanova JL. Inborn errors of anti-viral interferon immunity in humans. *Curr Opin Virol*. 2011; 1:487–496. [PubMed: 22347990]
25. Lopez CB, Hermesh T. Systemic responses during local viral infections: type I IFNs sound the alarm. *Current opinion in immunology*. 2011; 23:495–499. [PubMed: 21752617]
26. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. *Nature reviews*. 2005; 5:675–687.

27. Novikov A, et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1 β production in human macrophages. *J Immunol.* 2011; 187:2540–2547. [PubMed: 21784976]
28. Pandey AK, et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. *PLoS Pathog.* 2009; 5:e1000500. [PubMed: 19578435]
29. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. *The Journal of experimental medicine.* 2007; 204:987–994. [PubMed: 17452523]
30. Stockinger S, et al. Production of type I IFN sensitizes macrophages to cell death induced by *Listeria monocytogenes*. *J Immunol.* 2002; 169:6522–6529. [PubMed: 12444163]
31. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature.* 2010; 466:973–977. [PubMed: 20725040]
32. Clemons RJ, Clemons-Miller A, Johnson SM, Williamson SK, Horn TD. Comparing therapy costs for physician treatment of warts. *J Drugs Dermatol.* 2003; 2:649–654. [PubMed: 14711145]
33. Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. *Arch. Dermatol.* 2005; 141:589–594. [PubMed: 15897380]
34. Rosentul DC, et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. *The Journal of infectious diseases.* 2011; 204:1138–1145. [PubMed: 21881131]
35. Netea MG, et al. Immune sensing of *Candida albicans* requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. *J. Clin. Invest.* 2006; 116:1642–1650. [PubMed: 16710478]
36. Oosting M, et al. TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of *Borrelia Spirochetes*. *PloS one.* 2011; 6:e25998. [PubMed: 21998742]
37. Lehrer RI, Cline MJ. Interactions of *Candida albicans* with human leukocytes and serum. *J. Bacteriol.* 1969; 98:996–1004. [PubMed: 4182532]
38. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol.* 2004; 3 Article3.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc.* 1995; 57:289–300.
40. Huang, Z. SIGMOD Workshop on Research Issues on Data Mining and Knowledge Discovery Tucson; AZ, USA. 1997.
41. Xing, EP.; Jordan, MJ.; Karp, RM. Eighteenth International Conference on Machine Learning. Brodley, CE.; Danyluk, AP., editors. Morgan Kaufmann; Williamstown, MA, USA: 2001. p. 601-608.
42. Witten, IH.; Frank, E.; Hall, MA. Data mining: practical machine learning tools and techniques. Edn. 3rd Edition. Morgan Kaufmann.; 2011.
43. Langley, P.; Iba, W.; Thompson, K. Tenth National Conference on Artificial Intelligence. Swartout, WR., editor. The MIT Press; San Jose, CA, USA: 1992. p. 223-228.
44. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics.* 2005; 21:263–265. [PubMed: 15297300]
45. Purcell, S. Edn. PLINK 1.07 <http://pngu.mgh.harvard.edu/purcell/plink/>
46. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics.* 2007; 81:559–575. [PubMed: 17701901]
47. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics.* 2009; 25:1105–1111. [PubMed: 19289445]
48. Roberts A, Pimentel H, Trapnell C, Pachter L. Identification of novel transcripts in annotated genomes using RNA-Seq. *Bioinformatics.* 2011; 27:2325–2329. [PubMed: 21697122]




Figure 1. Transcriptional responses to *Candida*

(a) K-means clustering identifies shared and specific gene signatures in response to infection or stimulation. For example, clusters 21 and 25 indicate common inflammatory genes (details in Supplementary Fig. S2) that are significantly differentially induced genes (Benjamini-Hochberg-adjusted- $p < 0.05$, fold-change > 2) in response to *Borrelia burgdorferi*, *Candida albicans*, *E.coli*-derived LPS, and *Mycobacterium tuberculosis* (M.tb), compared to RPMI stimulations (Untreated), while clusters 7, 11 and 20 identify *Candida*-dominant response genes. Signal-to-noise ratio relative to untreated is shown in the heatmap. (b) Using feature selection, naïve Bayes classifier and 10-fold cross-validation, a 101-transcript feature set was identified from 693 differentially expressed transcripts shown in (a), which distinguishes *Candida* from the other stimulants and an area under the ROC (Receiver operating characteristic) curve of 97.8%, indicating a high discriminative value. The expression profile (Z-transformed) of this feature set is displayed. (c) Principal component analysis (PCA) of the *Candida*-response signature. Data from each individual sample is plotted along the three main principal components (PC1, PC2, PC3). The three main principal components account for 45% of the total variance in gene expression. Samples from the various stimulations and infections are color coded as follows: *Candida albicans* (2h: bright red; 24 hr: dark red), *Borrelia burgdorferi* (Green), *E.coli*-derived LPS (Blue), *Mycobacterium tuberculosis* (M.tb) (Purple) and untreated (Yellow). (d) Enrichment analysis (MetaCore pathways) of the 101-transcript feature set reveals a striking enrichment of the interferon (IFN) signaling pathway. Supplementary Table S2 displays all the signaling/biological processes shown and their enrichment p-values.




Figure 2. SNPs of type I IFN responsive genes are associated with susceptibility to Candidemia Regional association plots, at (a) *STAT1* region (b) *CCL8/CCL13* region (c) *SP110* region and (d) *PSMB8* region, showing chromosome position in the x-axis and the $-\log$ of logistic P values for each SNP in the y-axis. Blue diamond indicates the top P value; while orange and yellow diamonds indicates r^2 ranges of 0.6 to 0.8 and 0.4 to 0.59, respectively with the top associated SNP. SNP names shown are as in dbSNP130 where available. Otherwise, the Illumina ImmunoChip manifest name is shown. For example 1kg_17_29697448 indicates the location of SNP on chromosome 17 at position 29697448 (hg18).




Figure 3. SNPs of type I IFN responsive genes are associated with *Candida*-induced cytokine levels

Correlation plots showing the association between genotypes in the x-axis and cytokines levels in the y-axis. Association between (a) TNF-alpha levels and genotypes at *IRF1* SNP rs2548997, (b) IL-10 levels and genotypes at *IRF1* SNP rs1124211, (c) TNF-alpha and genotype at *STAT1* SNP rs2280234 and (d) IL-6 levels and genotypes at *STAT1* SNP rs41511150.




Figure 4. Type I IFNs skew cytokine production from a Th1 towards a Th17 response
(a) $5 \cdot 10^5$ PBMC in a volume of 200 μ L, were stimulated for seven days, in the presence of 10% human pooled serum, with live *Candida albicans* ($1 \cdot 10^6$ /mL), *in duplo*. IFN- α and IFN- β were measured in cell culture supernatants using ELISA. **(b)** $5 \cdot 10^5$ PBMC in a volume of 200 μ L, were stimulated for one and two days, with heat-killed *Candida albicans* ($1 \cdot 10^6$ /mL), in the absence of presence of anti-IFN- α / β R2, *in duplo*. IFN- γ , IL-1 β and TNF- α were measured in cell culture supernatants using ELISA. **(c)** $5 \cdot 10^5$ PBMC in a volume of 200 μ L, were stimulated for two and seven days, with heat-killed *Candida albicans* ($1 \cdot 10^6$ /mL), in the absence of presence of IFN- α or IFN- β , *in duplo*. When cells were cultured for seven days, this was done in the presence of 10 % human pooled serum. IFN- γ , IL-17 and IL-22 were measured in cell culture supernatants using ELISA. **(a,b,c)** After stimulation, supernatants were pooled and stored at -20°C until further assayed. Data were analyzed using the Wilcoxon signed rank test. Data are presented as mean + SEM.




Figure 5. Expression of type I IFN pathway genes in patients with a STAT1 mutation

Reduced expression of type I IFN pathway genes in patients with a STAT1 mutation ($n = 2$, with patients measured twice), and healthy controls ($n = 8$). $5 \cdot 10^5$ PBMC in a volume of $200 \mu\text{L}$, were stimulated for 24 hours, with RPMI, *E. coli*-derived LPS (10 ng/mL), heat-killed *Candida albicans* ($1 \cdot 10^6/\text{mL}$), or heat-killed *Mycobacterium tuberculosis* ($1 \mu\text{g/mL}$). mRNA was isolated from cell lysates using TRIzol. Transcription of IFN- β , IRF3, IRF9, IRF5, IRF7, ISG15, IFI44 and IFI44L was measured using qPCR. Data are presented as mean + SEM.



Figure 6. Heatmap of response of CMC patients and controls to *Candida albicans* in vitro stimulation

In this analysis the standardized fold change gene expression in stimulated vs. unstimulated cells was calculated. The scale of this heatmap is given as standardized log2 fold change with a range from -1.8 (blue) to $+1.8$ (red).